Equasens (0R9T) AI Stock Analysis

Equasens

(LSE:0R9T)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Durable profitabilityEquasens maintains strong profitability, with net margins generally in the high-teens to low-20s and operating margin near 20% in 2025. This indicates an established software and services model capable of producing meaningful earnings while supporting reinvestment and shareholder returns.

Negative Factors

Margin compressionAlthough profitability remains solid, the decline in margins from the stronger 2021–2023 period indicates that earnings are not expanding as efficiently as before. Continued compression could reduce operating leverage, limit reinvestment capacity, and make future profit growth more dependent on revenue expansion.

Equasens (0R9T) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: EUR 402.92M
Dividend Yield: 5.19%
Average Volume (3M): 666
Price to Earnings (P/E): 9.9
Beta (1Y): 0.42
Revenue Growth: 9.04%
EPS Growth: 13.05%
Country: UK
Employees: 1,462
Sector: General
Sector Strength: 55
Industry: Software - Application

Equasens Business Overview & Revenue Model

Company Description

Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their netwo...

Equasens Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

GB:0R9T against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:ALCGM	60Neutral	EUR 133.03M	-9.06	-5.44%	―	-0.98%	―
FR:ALERS	58Neutral	EUR 258.39M	37.57	3.89%	―	6.28%	204.56%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
FR:ALMDT	43Neutral	EUR 180.85M	-3.00	271.64%	―	2.16%	-5.26%

* General Sector Average

Performance Comparison

GB:0R9T and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0R9T	Equasens Société	26.95	-9.47	-26.01%
FR:ALCGM	Cegedim SA	9.70	-2.05	-17.45%
FR:ALERS	Eurobio-Scientific SA	26.30	2.15	8.90%
FR:ALMDT	Median Technologies	3.69	0.79	27.24%
FR:ALBIO	Biosynex SA	0.84	0.23	37.05%
FR:ABLD	ABL Diagnostics SA	2.28	-1.59	-41.10%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Equasens AI Stock Analysis